IBRO Neuroscience Reports (Oct 2023)

SEVERE ALZHEIMER'S DISEASE PATIENTS SHOW SAFE AND SIGNIFICANT IMPROVEMENT IN 6 MONTH BRYOSTATIN TRIAL - IN THE ABSENCE OF MEMANTINE

Daniel Alkon

Affiliations

Daniel Alkon: Synaptogenix, Inc., Neurodegeneration, New York, NY., United States of America

Journal volume & issue: Vol. 15
pp. S354 – S355

Abstract

No abstracts available.

Published in IBRO Neuroscience Reports

ISSN: 2667-2421 (Online)
Publisher: Elsevier
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Neurosciences. Biological psychiatry. Neuropsychiatry
Website: https://www.journals.elsevier.com/ibro-neuroscience-reports

About the journal